Scholar Rock Holding Corporation (SRRK)

Nasdaq: SRRK · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018

Full chart Alerts Compare

Grade4.8

◀ Past 3.8● Present 4.3▶ Future 5.8

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$0.00-100.0%

Net income-$378M-53.5%

Earnings per share$-3.29-33.2%

Operating cash flow-$300M-49.3%

Cash$327M+81.6%

Debt$99.7M+98.8%

Shareholders’ equity$245M-33.4%

Shares, diluted114.7M+14.9%

Return on equity-154.0%

The recordfrom its filings

Filings in 202680

Newest filingNov 10 · 10-Q

Annual reportMar 3, 2026

Quarterly reportNov 10, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$19.4M

Insider buys, 12 months$12.0M

Patents granted30

Filer categoryNon-accelerated filer

Trailing twelve months to Jun 2026Revenue $0.00the four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 1, 2026 · SEC EDGAR · Form 144

Notice of intended sale

Open the filing on sec.gov

Sep 25, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 23, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 15, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Scholar Rock Holding Corporation is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Cambridge, MA.

Newest on the record

Quarterly report on Nov 10. Before it, current report on Nov 10.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About SRRK

Scholar Rock Holding Corporation is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Cambridge, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $0 thousand and a loss of $378 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersCambridge, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2018

Fiscal year endsDec 31

SEC number (CIK)1727196

Peers on fileALLO, SANA, CGEM, GLUE

Who runs it

Financial performance

In fiscal 2025 Scholar Rock Holding’s revenue was $0, down 100.0% from $33.19 million the year before. It made a net loss of $377.9 million.

Annual report, filed Mar 3, 2026.

Financial statements

The grade

Scholar Rock Holding grades 4.8 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Five of the nine metrics are read as filed and four are SI estimates, each with its reasoning.

◀ Past3.8

● Present4.3

▶ Future5.8

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton SRRK · research, not advice